Loading stock data…
BRKR
$43.27-0.89 (-2.02%)
After Hours$42.88-0.39 (-0.90%)· Last close May 11
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bruker Corporation in the Healthcare sector is trading at $43.27. The stock is currently 23% below its 52-week high of $56.22, remaining 9.6% above its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why BRKR maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.27
Potential Upside
5%
Whystock Fair Value$45.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$48.86+12.9%
Range$35.00 – $60.00
Fundamentals
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BS...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Strong income play. Yield provides a meaningful total return floor.
50.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.24%
Volume
Today's trading volume
2.76M
Recent News
Bruker (BRKR) Q1 2026 Earnings Transcript
In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
Bruker Q1 Earnings Call Highlights
Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bruker’s (NASDAQ:BRKR) Q1 CY2026: Strong Sales
Scientific instrument company Bruker (NASDAQ:BRKR). announced better-than-expected revenue in Q1 CY2026, with sales up 2.7% year on year to $823.4 million. The company expects the full year’s revenue to be around $3.59 billion, close to analysts’ estimates. Its non-GAAP profit of $0.31 per share was 34.8% above analysts’ consensus estimates.